Assessment of quality of life

BEHAVIORAL3 trials

Sponsors

University Hospital, Strasbourg, France, Queen Mary University of London

Conditions

Inflammatory Bowel DiseasesParkinson Disease

Phase 2

Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

CompletedNCT03947216

University Hospital, Strasbourg, FranceParkinson Disease

Start: 2020-10-23End: 2024-06-17Updated: 2026-03-16

Unknown Phase

Mechanism of Chronic Pain in Patients With IBD

RecruitingNCT04995224

Queen Mary University of LondonInflammatory Bowel Diseases

Start: 2021-07-26End: 2025-12-31Target: 25600Updated: 2025-07-24

Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

Not yet recruitingNCT06754553

University Hospital, Strasbourg, FranceParkinson Disease

Start: 2025-02-28End: 2026-02-28Target: 100Updated: 2025-01-01